Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study
NCT ID: NCT04835324
Last Updated: 2022-03-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
650 participants
OBSERVATIONAL
2020-10-01
2022-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main observational goals include overall survival(OS), 6 month OS rate, 1 year OS rate, and treatment time failure (TTF), other study goals include objective response rate( ORR)、Disease control rate（DCR）and adverse event(AE) of regorafenib.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Real-World Effectiveness of Regorafenib in the Treatment of Patients With Metastatic Colorectal Cancer
NCT05023720
Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients
NCT05426811
Regorafenib in Taiwan Metastatic Colorectal Cancer (mCRC) Patients
NCT03829852
Observational Study on the Patients With Rectal Cancer
NCT02312284
Neoadjuvant FOLFOX6 Chemotherapy With or Without Radiation in Rectal Cancer
NCT01211210
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The pathological type of colorectal tumor was adenocarcinoma；
3. Patients with recurrent or metastatic, unresectable advanced colorectal cancer；
4. Patients who received regorafenib at least one period treatment.
Exclusion Criteria
2. Patients with other malignant tumors within 5 years before regorafenib treatment, except for cured cervical carcinoma in situ, skin squamous cell carcinoma or basal cell carcinoma, early papillary thyroid carcinoma, etc.;
3. The investigator deems that there are other factors that are not suitable for patients who participate in this study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Hospital
OTHER_GOV
Jiangsu Cancer Institute & Hospital
OTHER
The Affiliated Hospital of Qingdao University
OTHER
Shanxi Province Cancer Hospital
OTHER
Affiliated Hospital of Hebei University
OTHER
Shandong Cancer Hospital and Institute
OTHER
The First Affiliated Hospital of Zhengzhou University
OTHER
Hebei Medical University Fourth Hospital
OTHER
First Hospital of China Medical University
OTHER
Chinese Academy of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Aiping Zhou
Chief Physician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yunbo Zhao
Role: STUDY_CHAIR
Beijing Hospital
Liangjun Zhu
Role: STUDY_CHAIR
Jiangsu Cancer Institute & Hospital
Zimin Liu
Role: STUDY_CHAIR
The Affiliated Hospital of Qingdao University
Wei Bai
Role: STUDY_CHAIR
Shaanxi Provincial Cancer Hospital
Aimin Zang
Role: STUDY_CHAIR
Affiliated Hospital of Hebei University
Bo Liu
Role: STUDY_CHAIR
Shandong Cancer Hospital and Institute
Hong Zong
Role: STUDY_CHAIR
The First Affiliated Hospital of Zhengzhou University
Shengmian Li
Role: STUDY_CHAIR
The fourth hospital of Hebei medical university and hebei cancer hospital
Xiujuan Qu
Role: STUDY_CHAIR
First Hospital of China Medical University
Aiping Zhou
Role: PRINCIPAL_INVESTIGATOR
Cancer Hospital Chinese Academy of Medical Science
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cancer Hospital,Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
National Cancer Center/Cancer Hospital, Chinese ACademy of Medical Sciences and Peking Union Medical College
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Qu W, Liu Z, Chen X, Liu B, Zhao Y, Yan H, Qu X, Li S, Zang A, Sun Y, Zhu L, Zhou A. Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: a multicenter, real-world retrospective study in China. BMC Cancer. 2024 Jan 2;24(1):22. doi: 10.1186/s12885-023-11700-w.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ChineseAcademyMedicalSciences
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.